Perfil de resistencia de Pseudomona aeruginosa y Escherichia coli en pacientes del servicio de Medicina Interna de un Hospital, setiembre 2019 - febrero 2020
No Thumbnail Available
Date
2021
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
El presente informe tuvo como objetivo evaluar el perfil de resistencia de Pseudomona aeruginosa y Escherichia coli en pacientes del servicio de Medicina Interna de un hospital, en el periodo setiembre 2019 - febrero 2020. Esta investigación se realizó por el método descriptivo-retrospectivo transversal, durante el periodo setiembre 2019 - febrero del 2020, basado en la revisión de antibiogramas recolectados de las historias clínicas de los pacientes del servicio de Medicina Interna durante el periodo establecido. Los aislamientos de Escherichia coli y Pseudomona aeruginosa fueron 22 cada uno del total de cultivos positivos solicitados del servicio. Los antibióticos en los que se encontró mayor resistencia para Escherichia coli fueron sulfametoxazol / trimetoprima 100%, ampicilina 90,91%, aztreonam 36,36%, ceftazidima 77,27%, cefotaxima 81,82 %, cefuroxima 72,73%, ciprofloxacino 77,27% y levofloxacino 59,09%. En Pseudomona aeruginosa fueron los antimicrobianos como ceftazidima, 72,73% ciprofloxacino 72,73%, amikacina 59,09%, aztreonam 63,64%, cefepima 54,55%, imipenem 68,18%, gentamicina 59,9 %, levofloxacino 63,64%, meropenem 59,09%, tobramicina 59,09% y piperacilina/tazobactam 45,45%. Se concluye un alto porcentaje de resistencia de Escherichia coli y Pseudomona aeruginosa frente a los antimicrobianos más comunes para el tratamiento de las patologías mencionadas.
ABSTRACT The objective of this report was to evaluate the resistance profile of Pseudomona aeruginosa and Escherichia coli in patients of the Internal Medicine service of a hospital, in the period September 2019 - February 2020. This research was carried out by the cross-sectional descriptive-retrospective method, during the period September 2019 - February 2020, based on the review of antibiograms collected from the medical records of the patients of the Internal Medicine service during the established period. The isolates of Escherichia coli and Pseudomona aeruginosa were 22 each of the total of positive cultures requested from the service. The antibiotics with the greatest resistance to Escherichia coli were sulfamethoxazole / trimethoprim 100%, ampicillin 90.91%, aztreonam 36.36%, ceftazidime 77.27%, cefotaxime 81.82%, cefuroxime 72.73%, ciprofloxacin 77.27% and levofloxacin 59.09%. In Pseudomonas aeruginosa, antimicrobials such as ceftazidime, 72.73%, ciprofloxacin 72.73%, amikacin 59.09%, aztreonam 63.64%, cefepime 54.55%, imipenem 68.18%, gentamicin 59.9%, levofloxacin were 63.64%, meropenem 59.09%, tobramycin 59.09% and piperacillin / tazobactam 45.45%. It is concluded a high percentage of resistance of Escherichia coli and Pseudomona aeruginosa against the most common antimicrobials for the treatment of the mentioned pathologies.
ABSTRACT The objective of this report was to evaluate the resistance profile of Pseudomona aeruginosa and Escherichia coli in patients of the Internal Medicine service of a hospital, in the period September 2019 - February 2020. This research was carried out by the cross-sectional descriptive-retrospective method, during the period September 2019 - February 2020, based on the review of antibiograms collected from the medical records of the patients of the Internal Medicine service during the established period. The isolates of Escherichia coli and Pseudomona aeruginosa were 22 each of the total of positive cultures requested from the service. The antibiotics with the greatest resistance to Escherichia coli were sulfamethoxazole / trimethoprim 100%, ampicillin 90.91%, aztreonam 36.36%, ceftazidime 77.27%, cefotaxime 81.82%, cefuroxime 72.73%, ciprofloxacin 77.27% and levofloxacin 59.09%. In Pseudomonas aeruginosa, antimicrobials such as ceftazidime, 72.73%, ciprofloxacin 72.73%, amikacin 59.09%, aztreonam 63.64%, cefepime 54.55%, imipenem 68.18%, gentamicin 59.9%, levofloxacin were 63.64%, meropenem 59.09%, tobramycin 59.09% and piperacillin / tazobactam 45.45%. It is concluded a high percentage of resistance of Escherichia coli and Pseudomona aeruginosa against the most common antimicrobials for the treatment of the mentioned pathologies.
Description
Keywords
Escherichia coli, Pseudomona aeruginosa, resistencia, antibióticos.